吡达隆 | 7035-04-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 吡达隆
• 中文别名: 吡苯呋喃；吡苯呋喃吡达隆；吡啶氧茚
• 英文名称: 4-(benzofuran-2-yl)pyridine
• 英文别名: Pyridarone；4-(1-benzofuran-2-yl)pyridine
• CAS: 7035-04-3
• 化学式: C₁₃H₉NO
• mdl: MFCD00866973
• 分子量: 195.221
• InChiKey: LGTULKCVKOMQDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  吡达隆 在 过氧乙酸 作用下， 生成 4-benzofuran-2-yl-pyridine 1-oxide
  参考文献：
  名称：

  Ziegler,H.J. et al., Chimica Therapeutica, 1971, vol. 6, p. 159 - 166

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯甲基吡啶盐酸盐 在 三氟甲磺酸 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 吡达隆
  参考文献：
  名称：

  布朗斯台德酸催化烷基吡啶的分子内苄基环化†

  摘要：

  在布朗斯台德酸催化剂的存在下，结合到2-和4-烷基吡啶的侧链中的醛和酮亲电子试剂与吡啶苄基碳一起参与分子内的醛醇状缩合。以β-酮酰胺侧链为特征的吡啶在10摩尔％TfOH的存在下进行环化，以高收率得到吡啶基取代的羟基内酰胺。已发现这些产物在各种条件下均能抵抗进一步的脱水，但是用亚硫酰氯处理引发了异常的脱水/氧化反应顺序。相反，与胺键合的脂族醛与吡啶的酸催化环化生成吡啶基取代的脱氢哌啶产物。相似地，

  DOI：

  10.1039/c3ob42039f

文献信息

• One-pot synthesis of useful heterocycles in medicinal chemistry using a cascade strategy
  作者：Guiyong Wu、Weiyu Yin、Hong C. Shen、Yong Huang

  DOI：10.1039/c2gc16457d

  日期：——

  To access useful heterocycles in medicinal chemistry such as pyridazinones, dihydropyrimidinones, and dihydropyrimidinthiones, a “green” mild and highly efficient one-pot triple cascade was developed involving a Claisen–decarboxylation, electrophilic reaction, and subsequent heterocyclization. In addition, indazoles and benzofurans could also be constructed via a double cascade. To develop the cascade process, a direct Claisen–decarboxylation reaction was firstly optimized. This reaction can then couple with electrophilic reactions including alkylation, Michael addition or aldol reaction to enable the preparation of various aryl ketones in a one-pot fashion.

  为了在药物化学中获得有用的杂环化合物，如吡嗪酮、二氢嘧啶酮和二氢嘧噻啶酮，开发了一种“绿色”的温和且高效的一锅三重级联反应，包括克莱森脱羧反应、电亲和反应以及随后的杂环化反应。此外，还可以通过双重级联反应构建吲哚并和苯并呋喃。为了开发这个级联过程，首先对直接的克莱森脱羧反应进行了优化。该反应随后可以与包括烷基化、米哈伊尔加成或醛醇反应在内的电亲和反应耦合，从而能够以一锅法制备各种芳基酮。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Binary Co‐Crystals of Quercetin: Synthesis, Structure, and Spectroscopic Characterization
  作者：Urszula Maciołek、Ewaryst Mendyk、Marcin Kuśmierz、Anna E. Kozioł

  DOI：10.1002/cplu.202300166

  日期：2023.7

  Four new co-crystals of quercetin, with the co-formers being N-aromatic derivatives, have been synthesized and characterized. The co-former molecules bind by the hydrogen bonds to quercetin via the peripheral hydroxyl groups. X-ray crystallography confirmed the presence of neutral co-former molecules while the XPS studies, carried out under high vacuum, showed the O−H…N hydrogen bond with partial proton

  合成并表征了四种新的槲皮素共晶，其共形成物是N-芳香族衍生物。共形成分子通过外围羟基通过氢键与槲皮素结合。X射线晶体学证实了中性共聚体分子的存在，而在高真空下进行的XPS研究显示了O−H…N氢键，部分质子从槲皮素的羟基转移到共聚体的吡啶环上。以前的。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• Benzofuran-derived benzylpyridinium bromides as potent acetylcholinesterase inhibitors
  作者：Farzaneh Baharloo、Mohammad Hossein Moslemin、Hamid Nadri、Ali Asadipour、Mohammad Mahdavi、Saeed Emami、Loghman Firoozpour、Razieh Mohebat、Abbas Shafiee、Alireza Foroumadi

  DOI：10.1016/j.ejmech.2015.02.009

  日期：2015.3

  A series of benzofuran-based N-benzylpyridinium derivatives 5a-o were designed and synthesized as novel AChE inhibitors. The synthetic pathway of the compounds involved the preparation of 4-(benzofuran-2-yl)pyridine intermediates via the reaction of different salicylaldehyde derivatives and 4-(bromomethyl)pyridine, followed by intramolecular cyclization. Subsequently, the 4-(benzofuran-2-yl) pyridines were N-benzylated by using appropriate benzyl bromide to afford the final product 5a-o. The results of in vitro AChE activity evaluation of synthesized compounds revealed that all compound had potent anti-AChE activity comparable or more potent than standard drug donepezil. The N-(3,5-dimethylbenzyl) derivative 5e with IC50 value of 4.1 nM was the most active compound, being 7-fold more potent than donepezil. (C) 2015 Elsevier Masson SAS. All rights reserved.